Loading clinical trials...
Loading clinical trials...
A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy
Conditions
Interventions
Felzartamab
Placebo
Locations
60
United States
FOMAT Medical Research - FOMAT - HyperCore - PPDS
Oxnard, California, United States
Amicis Research Center, Vacaville
Vacaville, California, United States
Mayo Clinic Hospital - Methodist Campus
Rochester, Minnesota, United States
MedResearch INC
El Paso, Texas, United States
Core Research Group
Milton, Queensland, Australia
Sunshine Hospital - Australia
Saint Albans, Victoria, Australia
Start Date
August 31, 2021
Primary Completion Date
February 6, 2023
Completion Date
May 6, 2024
Last Updated
February 7, 2025
Lead Sponsor
HI-Bio, A Biogen Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions